E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
First Relapsed or Refractory Acute Myeloid Leukemia |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060558 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10054296 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Compare overall survival (OS) between treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine |
|
E.2.2 | Secondary objectives of the trial |
• Compare complete remission (CR) rate based on International Working Group (IWG) response criteria, between treatment groups Compare safety and tolerability between treatment groups |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
FARMACOCINETICA/FARMACODINAMICA: Versione:addendum Data:2010/09/03 Titolo:Sottostudio di elettrocardiografia e farmacocinetica (addendum al protocollo VOS-AML-301, datato 03 Settembre 2010 (solo per gli Stati Uniti). Obiettivi:Circa 30 pazienti in ogni gruppo di trattamento in 15-20 centri negli Stati Uniti saranno arruolati in questo sottostudio. L`effetto sulla ripolarizzazione cardiaca, come misura del QTcF, sara` valutata nei pazienti trattati con vosaroxin (90 mg/m2, la piu` alta dose somministrata nello studio) verso placebo e citarabina. Al giorno 1 e 4 dell`induzione 1,gli ECG digitali a 12 derivazioni saranno registrati continuativamente utilizzando un monito Holter prima di ogni dose di vosaroxin o placebo fino a 23 ore dopo l`inizio della somministrazione del farmaco. Gli ECG saranno letti e la valutazione delle onde QT sara` effettuata da un cardiologo all`oscuro del trattamento assegnato presso la la struttura dei servizi di sicurezza cardiaca centrale. Occasionalmente, corrispondenti campioni di sangue saranno ottenuti per determinare le concentrazioni di vosaroxin, citarabina, e i loro principali metaboliti per valutazioni di PK, e PK-PD
|
|
E.3 | Principal inclusion criteria |
1. Able to understand and provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization, as appropriate 2. At least 18 years of age 3. Diagnosis of acute myeloid leukemia (AML) by World Health Organization (WHO) classification 4. Relapsed or refractory AML with at least 5% blasts by bone marrow biopsy or aspirate, or at least 1% blasts in peripheral blood, and meeting the criteria for relapsed or refractory AML detailed in section 4.1 of the protocol 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 6. Local clinical laboratory values as follows: - Serum creatinine ≤ 2.0 mg/dL - Total bilirubin ≤ 1.5 x the upper limit of normal (ULN), unless due to Gilbert’s syndrome - Aspartate aminotransferase (AST) ≤ 2.5 x ULN - Alanine aminotransferase (ALT) ≤ 2.5 x ULN 7. Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) 8. Clinically significant nonhematologic toxicity after prior chemotherapy has recovered to grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or newer 9. Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative urine or serum pregnancy test within 14 days before the first vosaroxin or placebo administration, and must agree to use an adequate method of contraception during the study until 30 days after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 30 days after the last treatment |
|
E.4 | Principal exclusion criteria |
1. Acute promyelocytic leukemia (APL) 2. More than 2 cycles of induction therapy for AML 3. Refractory to or relapsed ≤ 90 days after any induction or consolidation therapy with an intermediate or high dose cytarabine (IDAC or HIDAC) regimen containing a cumulative dose of ≥ 5 g/m2 cytarabine 4. Transplantation for AML (either allogeneic or autologous) ≤ 90 days of randomization or on active immunosuppressive therapy for graft versus host disease (GVHD) within 2 weeks before the first dose of vosaroxin or placebo 5. Central nervous system (CNS) involvement of active AML 6. Other active malignancies (including other hematologic malignancies) or other malignancies within the last 12 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia 7. Uncontrolled active infection of any type - Infections under control with antibiotic treatment are acceptable - Chronic hepatitis is acceptable 8. Uncontrolled invasive fungal infection (positive blood or tissue culture) 9. History of myocardial infarction (MI), unstable angina, cerebrovascular accident, or transient ischemic attack (CVA/TIA) within 3 months before the first dose of vosaroxin or placebo 10. Prior or current therapy: - Hydroxyurea or other oral medications to reduce blast count within 24 hours before the first dose of vosaroxin or placebo - Treatment with an investigational product within 14 days before the first dose of vosaroxin or placebo, or not recovered from all acute effects of previously administered investigational products 11. Hemodialysis or peritoneal dialysis required 12. Prior exposure to vosaroxin 13. Pregnant or breastfeeding 14. Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator or medical monitor |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is overall survival (OS) in the intent-to-treat population. Analysis of OS will be based on the log-rank test weighted to account for the adaptive design. Kaplan-Meier methods will be used to estimate OS for each treatment group. Sensitivity analyses will be performed to assess the effect of subsequent therapy, and specifically transplantation, on OS. One formal interim efficacy analysis will be performed after reaching 187 events (deaths) (50% of the required number of 375 events). At the discretion of the data and safety monitoring board (DSMB), one of the following actions will be taken at the interim analysis: terminate for efficacy, terminate for futility, increase the accrual to a maximum of 750 patients and extend the observations in the study beyond the prespecified 375 events, or continue the study as planned. The primary safety endpoint is 30- and 60-day all cause mortality, summarized with point estimates and 95% confidence intervals. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 67 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
dopo l`ultima visita dell`ultimo pz,il FU raccogliera` informazioni sulla sopravvivenza di tutti i pz(endpoint primario)fino a morte, ritiro del ICF, perdita al FU (la sopravvivenza media attesa e` di 5-7 mesi). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |